Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, and pharmacokinetics study of KarXT and a dual-burst release formulation of xanomeline with immediate-release trospium chloride in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychiatric Disorders

Drugs mentioned

• KarXT (xanomeline-trospium)
• Xanomeline with Immediate-release Trospium Chloride (xanomeline; trospium chloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psychiatric Disorders | Phase 1 | Status: COMPLETED